☰

Duane B. Welling, Ph.D. - Publications

Affiliations: 
2003 Ohio State University, Columbus, Columbus, OH 
Area:
Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

22 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Allaway R, Angus SP, Beauchamp RL, Blakeley JO, Bott M, Burns SS, Carlstedt A, Chang LS, Chen X, Clapp DW, Desouza PA, Erdin S, Fernandez-Valle C, Guinney J, ... ... Welling DB, et al. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. Plos One. 13: e0197350. PMID 29897904 DOI: 10.1371/Journal.Pone.0197350  0.635
2016 Oblinger JL, Burns SS, Akhmametyeva EM, Huang J, Pan L, Ren Y, Shen R, Miles-Markley B, Moberly AC, Kinghorn AD, Welling DB, Chang LS. Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas. Neuro-Oncology. PMID 26951381 DOI: 10.1093/Neuonc/Now032  0.614
2015 Chow HY, Dong B, Duron SG, Campbell DA, Ong CC, Hoeflich KP, Chang LS, Welling DB, Yang ZJ, Chernoff J. Group I Paks as therapeutic targets in NF2-deficient meningioma. Oncotarget. 6: 1981-94. PMID 25596744 DOI: 10.18632/Oncotarget.2810  0.68
2014 Petrilli A, Copik A, Posadas M, Chang LS, Welling DB, Giovannini M, Fernández-Valle C. LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2. Oncogene. 33: 3571-82. PMID 23934191 DOI: 10.1038/onc.2013.320  0.664
2013 Spear SA, Burns SS, Oblinger JL, Ren Y, Pan L, Kinghorn AD, Welling DB, Chang LS. Natural compounds as potential treatments of NF2-deficient schwannoma and meningioma: cucurbitacin D and goyazensolide. Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 34: 1519-27. PMID 23928514 DOI: 10.1097/Mao.0B013E3182956169  0.593
2013 Burns SS, Akhmametyeva EM, Oblinger JL, Bush ML, Huang J, Senner V, Chen CS, Jacob A, Welling DB, Chang LS. Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth. Cancer Research. 73: 792-803. PMID 23151902 DOI: 10.1158/0008-5472.Can-12-1888  0.655
2012 Bush ML, Burns SS, Oblinger J, Davletova S, Chang LS, Welling DB, Jacob A. Treatment of vestibular schwannoma cells with ErbB inhibitors. Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 33: 244-57. PMID 22222570 DOI: 10.1097/Mao.0B013E31823E287F  0.608
2012 Jacob A, Oblinger J, Bush ML, Brendel V, Santarelli G, Chaudhury AR, Kulp S, La Perle KM, Chen CS, Chang LS, Welling DB. Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas. The Laryngoscope. 122: 174-89. PMID 22109824 DOI: 10.1002/Lary.22392  0.631
2011 Bush ML, Oblinger J, Brendel V, Santarelli G, Huang J, Akhmametyeva EM, Burns SS, Wheeler J, Davis J, Yates CW, Chaudhury AR, Kulp S, Chen CS, Chang LS, Welling DB, et al. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro-Oncology. 13: 983-99. PMID 21778190 DOI: 10.1093/Neuonc/Nor072  0.664
2009 Lee TX, Packer MD, Huang J, Akhmametyeva EM, Kulp SK, Chen CS, Giovannini M, Jacob A, Welling DB, Chang LS. Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells. European Journal of Cancer (Oxford, England : 1990). 45: 1709-20. PMID 19359162 DOI: 10.1016/J.Ejca.2009.03.013  0.63
2009 Chang LS, Welling DB. Molecular biology of vestibular schwannomas. Methods in Molecular Biology (Clifton, N.J.). 493: 163-77. PMID 18839347 DOI: 10.1007/978-1-59745-523-7_10  0.648
2009 Oblinger J, Bush ML, Wheeler J, Chen C, Jacob A, Welling DB, Chang L. HDAC-42 as a potential radiosensitizer for human schwannomas Otolaryngology - Head and Neck Surgery. 141: P81-P81. DOI: 10.1016/J.Otohns.2009.06.248  0.568
2007 Welling DB, Packer MD, Chang LS. Molecular studies of vestibular schwannomas: a review. Current Opinion in Otolaryngology & Head and Neck Surgery. 15: 341-6. PMID 17823551 DOI: 10.1097/Moo.0B013E3282B97310  0.572
2006 Chang LS, Jacob A, Abraham J, Lorenz M, Rock J, Akhmametyeva EM, Mihai G, Schmalbrock P, Chaudhury AR, Lopez R, Yamate J, John MR, Wickert H, Neff BA, Dodson E, ... Welling DB, et al. Growth of benign and malignant schwannoma xenografts in severe combined immunodeficiency mice. The Laryngoscope. 116: 2018-26. PMID 17075413 DOI: 10.1097/01.Mlg.0000240185.14224.7D  0.585
2006 Akhmametyeva EM, Mihaylova MM, Luo H, Kharzai S, Welling DB, Chang LS. Regulation of the neurofibromatosis 2 gene promoter expression during embryonic development. Developmental Dynamics : An Official Publication of the American Association of Anatomists. 235: 2771-85. PMID 16894610 DOI: 10.1002/Dvdy.20883  0.62
2006 Neff BA, Oberstien E, Lorenz M, Chaudhury AR, Welling DB, Chang LS. Cyclin D(1) and D(3) expression in vestibular schwannomas. The Laryngoscope. 116: 423-6. PMID 16540902 DOI: 10.1097/01.Mlg.0000195076.05466.6C  0.582
2006 Neff BA, Welling DB, Akhmametyeva E, Chang LS. The molecular biology of vestibular schwannomas: dissecting the pathogenic process at the molecular level. Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 27: 197-208. PMID 16436990 DOI: 10.1097/01.Mao.0000180484.24242.54  0.571
2002 Lasak JM, Welling DB, Akhmametyeva EM, Salloum M, Chang LS. Retinoblastoma-cyclin-dependent kinase pathway deregulation in vestibular schwannomas. The Laryngoscope. 112: 1555-61. PMID 12352662 DOI: 10.1097/00005537-200209000-00004  0.605
2002 Welling DB, Lasak JM, Akhmametyeva E, Ghaheri B, Chang LS. cDNA microarray analysis of vestibular schwannomas. Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 23: 736-48. PMID 12218628 DOI: 10.1097/00129492-200209000-00022  0.623
2002 Chang LS, Akhmametyeva EM, Wu Y, Zhu L, Welling DB. Multiple transcription initiation sites, alternative splicing, and differential polyadenylation contribute to the complexity of human neurofibromatosis 2 transcripts. Genomics. 79: 63-76. PMID 11827459 DOI: 10.1006/Geno.2001.6672  0.597
2000 Welling DB, Akhmametyeva EM, Daniels RL, Lasak JM, Zhu L, Miles-Markley BA, Chang LS. Analysis of the human neurofibromatosis type 2 gene promoter and its expression. Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. 123: 413-8. PMID 11020177 DOI: 10.1067/Mhn.2000.107683  0.62
2000 Welling DB, Chang LS. All in a name: schwannomin versus merlin. The American Journal of Otology. 21: 289. PMID 10733201  0.528
Show low-probability matches.